Search Results
May 28, 2025, 08:35 ET Cerby Raises $40M Series B to Automate Identity Security at Scale
access. It works horizontally across Enterprise Password Management (EPM), Identity and Access Management (IAM), Identity Governance and Administration (IGA), and Privileged Access Management (PAM) systems, helping customers extend protection to the applications and user identities that traditional tools
More news about: Cerby
May 27, 2025, 17:31 ET FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight
IgA Nephropathy Pipeline IgA Nephropathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgA nephropathy companies,
More news about: DelveInsight Business Research, LLP
May 23, 2025, 04:00 ET England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
advancement in the treatment of IgA nephropathy in the UK. "IgA nephropathy is a condition with an average age at diagnosis of around 40 years.6 Due to disease progression, a patient's kidneys may fail. Treatments, such as sparsentan, that have been developed for IgA nephropathy are urgently needed,
More news about: Vifor International AG (CSL Vifor)
May 23, 2025, 04:00 ET England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
advancement in the treatment of IgA nephropathy in the UK. "IgA nephropathy is a condition with an average age at diagnosis of around 40 years.6 Due to disease progression, a patient's kidneys may fail. Treatments, such as sparsentan, that have been developed for IgA nephropathy are urgently needed,
More news about: Vifor International AG (CSL Vifor)
May 22, 2025, 23:39 ET 耐賦康®被納入《中國成人IgA腎病及IgA血管炎臨床實踐指南（預審版本）》
1952.HK）是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，於5月21日宣佈耐賦康®（布地奈德腸溶膠囊，NEFECON®）被納入《中國成人IgA腎病及IgA血管炎臨床實踐指南（預審版本）》（以下簡稱為「指南預審版」），推薦對有疾病進展風險的IgA腎病患者進行9個月的布地奈德腸溶膠囊對因治療，不受蛋白尿水平的限制，以降低致病性IgA（Gd-IgA1）(2B)；耐賦康®作為一款靶向腸道黏膜的IgA腎病對因治療藥物，療效確切、安全性良好，為IgA腎病患者提供了新的治療選擇。這標誌著耐賦康®成為目前唯一同時獲得國內外指南推薦的IgA腎病對因治療藥物，證實了其作為IgA腎病一線治療基石的領導地位。
More news about: 雲頂新耀
May 12, 2025, 16:05 ET Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
three innovative compounds, including BHV-1300 (IgG degrader targeting with first target indication in Graves' disease), BHV-1400 (Gd-IgA1 degrader for IgA nephropathy), and BHV-1600 (β1AR AAb degrader targeting PPCM), and are advancing four additional degrader molecules in parallel.
More news about: Biohaven Ltd.
May 09, 2025, 08:05 ET Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
severity affecting special areas (e.g., scalp, genital and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint. b. The IGA is a five-point scale with a severity score ranging from 0 to 4, where 0 indicates clear,
More news about: Johnson & Johnson
May 06, 2025, 19:30 ET 雲頂新耀宣布耐賦康®獲得中國國家藥品監督管理局完全批准
®專為IgA腎病患者研制，每顆膠囊含布地奈德4mg，通過特殊的遲釋及緩釋雙重制劑工藝，將布地奈德靶向釋放於回腸末端的黏膜B細胞（包括派爾集合淋巴結），膠囊溶解後，三層包衣微丸持續穩定釋放布地奈德，高濃度覆蓋整個靶區域，從而減少誘發IgA腎病的半乳糖缺陷的IgA1抗體（Gd-IgA1）產生，進而干預發病機制上游階段，達到治療IgA腎病的作用。 2019年6月，雲頂新耀與Calliditas Therapeutics 簽訂獨家授權許可協議，獲得在大中華地區和新加坡開發以及商業化耐賦康®的權利。該協議於2022年3月擴展，將韓國納入雲頂新耀的授權許可范圍。
More news about: 雲頂新耀
May 05, 2025, 17:31 ET Intravenous Immunoglobulin (IVIG) Market Forecast to Surge During the Forecast Period (2025-2034) with Rising Demand for Autoimmune and Immunodeficiency Treatments | DelveInsight
established in the market. TAK-880, developed by Takeda, is a low IgA-IgG intravenous immunoglobulin formulation under investigation for treating primary immunodeficiency diseases, especially in patients with IgA hypersensitivity. It is currently undergoing regulatory filing with the FDA and
More news about: DelveInsight Business Research, LLP
May 01, 2025, 09:45 ET Cyrex Announces Publication in the Journal "Foods" on the Importance of Testing for the Contribution of Raw and Processed Foods to Autoimmunity
proteins, generating new immunodominant epitopes and neo-antigens that affect the body's immune response. These changes may provoke increased IgE, IgG, and IgA antibody responses compared to raw foods, potentially leading to heightened food sensitivities and autoimmunity through mechanisms like cross-reactivity
More news about: Cyrex Laboratories
Apr 30, 2025, 03:03 ET Omada annonce un investissement de la part de GRO et Kirk Kapital pour stimuler la prochaine phase de croissance et d'innovation dans le domaine de la gouvernance des identités.
habituelles. A propos d'OmadaOmada, leader mondial du marché de la gouvernance et de l'administration des identités (IGA), offre une solution IGA complète et cloud-native qui permet aux entreprises de se mettre en conformité, de réduire les risques et d'optimiser l'efficacité opérationnelle.
More news about: Omada
Apr 29, 2025, 17:31 ET FABHALTA Set to Disrupt Complement Inhibitor Market with Oral Convenience and Strong Efficacy | DelveInsight
IgA Nephropathy Market IgA Nephropathy Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends,
More news about: DelveInsight Business Research, LLP
Apr 29, 2025, 09:25 ET Omada anuncia inversión de GRO y Kirk Kapital
Administración de Identidades (IGA), ofrece una solución de IGA completa y nativa de la nube que permite a las organizaciones lograr el cumplimiento normativo, reducir el riesgo y maximizar la eficiencia operativa. Fundada en el año 2000, Omada se especializa en simplificar la IGA, ofreciendo soluciones innovadoras
More news about: Omada
Apr 29, 2025, 08:03 ET Omada Announces Investment from GRO and Kirk Kapital to Drive Next Phase of Growth and Innovation in Identity Governance
leader in Identity Governance and Administration (IGA), offers a full-featured, cloud-native IGA solution that enables organizations to achieve compliance, reduce risk, and maximize operational efficiency. Founded in 2000, Omada specializes in simplifying IGA, delivering innovative identity management solutions
More news about: Omada
Apr 29, 2025, 05:33 ET Omada kündigt Investition von GRO und Kirk Kapital an, um die nächste Wachstums- und Innovationsphase im Bereich Identity Governance voranzutreiben
and Administration (IGA) und bietet eine umfassende, Cloud-native IGA-Lösung, die Organisationen hilft, Compliance-Ziele zu erreichen, Risiken zu minimieren und die betriebliche Effizienz zu maximieren. Gegründet im Jahr 2000, spezialisiert sich Omada auf die Vereinfachung von IGA mit innovativen Lösungen
More news about: Omada
Apr 29, 2025, 04:03 ET Omada Announces Investment from GRO and Kirk Kapital to Drive Next Phase of Growth and Innovation in Identity Governance
leader in Identity Governance and Administration (IGA), offers a full-featured, cloud-native IGA solution that enables organizations to achieve compliance, reduce risk, and maximize operational efficiency. Founded in 2000, Omada specializes in simplifying IGA, delivering innovative identity management solutions
More news about: Omada
Apr 29, 2025, 02:00 ET CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
travere.com. About IgA Nephropathy (IgAN) IgAN, also called Berger's disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal
More news about: Vifor International AG (CSL Vifor)
Apr 29, 2025, 02:00 ET CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
travere.com. About IgA Nephropathy (IgAN) IgAN, also called Berger's disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal
More news about: Vifor International AG (CSL Vifor)
Apr 28, 2025, 17:31 ET Novartis' VANRAFIA Approval Disrupts IgA Nephropathy Market, Paving Way for New Therapeutic Paradigm | DelveInsight
IgA Nephropathy Pipeline IgA Nephropathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgA nephropathy companies,
More news about: DelveInsight Business Research, LLP
Apr 28, 2025, 12:27 ET Omada Named Winner of the Coveted Global InfoSec Awards During RSA Conference 2025
April 28, 2025 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration (IGA), is proud to announce that it has been named the winner of the Next Gen Identity and Access Management category at the Annual Global InfoSec
More news about: Omada
Apr 28, 2025, 09:54 ET Silverfort étend son offre de sécurité des identités non humaines au cloud pour offrir une sécurité de bout en bout des identités
réponse aux menaces de l'identité (ITDR), la gestion de la posture de sécurité des identités (ISPM), la gouvernance et l'administration de l'identité (IGA) et la sécurité des NHI. En élargissant sa capacité à sécuriser les NHI basées sur le cloud, Silverfort est devenu la première entreprise à fournir une
More news about: Silverfort Ltd
Apr 28, 2025, 09:00 ET Silverfort erweitert sein Angebot für die Sicherheit nicht-menschlicher Identitäten (NHIs) auf die Cloud und ermöglicht damit durchgängige Identitätssicherheit
in den Bereichen Identity Threat Detection and Response (ITDR), Identity Security Posture Management (ISPM), Identity Governance and Administration (IGA) und NHI Security. Mit dem erweiterten Schutz cloudbasierter NHIs ist Silverfort das erste Unternehmen, das skalierbare Sicherheit für alle Identitäten
More news about: Silverfort Ltd
Apr 28, 2025, 09:00 ET Silverfort Expands its Non-Human Identity (NHI) Security Offering to the Cloud for End-to-End Identity Security
offerings that span identity threat detection and response (ITDR), identity security posture management (ISPM), Identity Governance and Administration (IGA) and NHI security. By expanding its ability to secure cloud-based NHIs, Silverfort became the first company to provide seamless, scalable security for
More news about: Silverfort Ltd
Apr 28, 2025, 09:00 ET Silverfort amplía su oferta de seguridad de identidad no humana (NHI) a la nube
respuesta ante amenazas de identidad (ITDR), la gestión de la postura de seguridad de la identidad (ISPM), la gobernanza y administración de la identidad (IGA) y la seguridad de NHI. Al ampliar su capacidad para proteger NHI en la nube, Silverfort se convirtió en la primera empresa en ofrecer seguridad fluida
More news about: Silverfort Ltd
Apr 24, 2025, 09:00 ET Lumos Introduces Industry's First Autonomous Identity Platform, Redefining Policy Management & Lifecycle Automation
vulnerabilities. An IGA initiative is one of the most important pieces of an IAM program. However, IGA systems are complex, which often translates to the highest deployment cost. Gartner estimates that 50% of IGA deployments are in 'distress.' "Organizations deploying IGA systems will continue to
More news about: Lumos